Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Marimed (MRMD) Equity Average (2016 - 2025)

Marimed (MRMD) has disclosed Equity Average for 15 consecutive years, with $55.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 17.69% to $55.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $55.6 million, a 17.69% decrease, with the full-year FY2024 number at $64.2 million, up 0.97% from a year prior.
  • Equity Average was $55.6 million for Q3 2025 at Marimed, down from $57.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $80.4 million in Q3 2023 to a low of $11.4 million in Q1 2021.
  • A 5-year average of $53.4 million and a median of $57.4 million in 2025 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 1482.31% in 2021, then decreased 17.69% in 2025.
  • Marimed's Equity Average stood at $35.8 million in 2021, then soared by 52.49% to $54.6 million in 2022, then surged by 37.17% to $74.9 million in 2023, then dropped by 15.62% to $63.2 million in 2024, then fell by 11.97% to $55.6 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Equity Average are $55.6 million (Q3 2025), $57.4 million (Q2 2025), and $58.2 million (Q1 2025).